v3.26.1
Stockholders' Equity
6 Months Ended
Jun. 30, 2026
Stockholders' Equity  
Stockholders' Equity

Note 15. Stockholders' Equity

Share Buyback Program

Pursuant to the Company’s existing share buyback program, the Company purchased 2,283,375 and 3,656,720 shares of its common stock, during the three and six months ended June 30, 2026, for total consideration of $44.7 million and $74.2 million, respectively. The Company purchased 1,541,860 shares and 1,935,696 shares of its common stock during the three and six months ended June 30, 2025, for total consideration of $39.0 million and $50.0 million, respectively.

Since the inception of the program, the Company’s Board of Directors have authorized a total of $485.0 million in the share buyback program. The primary goal of the program is to offset dilution created by the Company’s equity compensation programs.

Purchases are made through open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions or other means as determined by the Company’s management and in accordance with the requirements of the SEC and applicable laws. The timing and actual number of treasury share purchases will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions. These treasury share purchases are accounted for under the cost method and are included as a component of treasury stock in the Company’s condensed consolidated balance sheets.

Amended and Restated 2015 Equity Incentive Plan

In February 2024, the Board of Directors approved the Company’s amended and restated 2015 Equity Incentive Plan, or the Amended 2015 Plan, which was subsequently approved by the Company’s stockholders, and accordingly, adopted by the Company in June 2024. The Amended 2015 Plan, among other things, extended the term of the 2015 Equity Incentive Plan, or the Original 2015 Plan, increased the number of shares available for issuance under the Original 2015 Plan, and removed the evergreen provision. The term of the Amended 2015 Plan will be extended indefinitely, however, the Company’s ability to grant incentive stock options thereunder will continue through February 2034.

As of June 30, 2026, the Company reserved an aggregate of 4,560,764 shares of common stock for future issuance under the Amended 2015 Plan.

2014 Employee Stock Purchase Plan

As of June 30, 2026, the Company has issued 1,563,625 shares of common stock under the ESPP and 436,375 shares of its common stock remain available for issuance under the ESPP.

In May 2026, the Company issued 120,579 shares at a purchase price of $16.02 per share under the ESPP. For the three and six months ended June 30, 2026, the Company recorded ESPP expense of $0.4 million and $0.7 million, respectively. For the three and six months ended June 30, 2025, the Company recorded ESPP expense of $0.4 million and $0.7 million, respectively.

Share-Based Award Activity and Balances

The Company accounts for share-based compensation payments in accordance with ASC 718, which requires measurement and recognition of compensation expense at fair value for all share-based payment awards made to employees and directors. Under these standards, the fair value of option awards and the option components of the ESPP awards are estimated at the grant date using the Black-Scholes option-pricing model. The fair value of RSUs is estimated at the grant date using the Company’s common share price. The Company records share-based compensation expense net of expected forfeitures. Compensation cost for all share-based payments granted with service-based graded vesting schedules is recognized using the straight-line method over the requisite service period.

The weighted-averages for key assumptions used in determining the fair value of options granted are as follows:

Three Months Ended

Six Months Ended

 

June 30, 

June 30, 

2026

  ​ ​ ​

2025

 

2026

  ​ ​ ​

2025

 

Average volatility

 

44.5

%  

41.6

%  

43.5

%

40.9

%

Average risk-free interest rate

 

4.3

%  

4.2

%  

4.0

%

4.2

%

Weighted-average expected life in years

 

5.7

5.7

6.2

6.2

Dividend yield rate

 

%  

%  

%

%

A summary of option activity under all plans for the six months ended June 30, 2026, is presented below:

Weighted-Average

Weighted-Average

Remaining

Aggregate

Exercise

Contractual

Intrinsic

Options

Price

Term (Years)

Value(1)

(in thousands)

Outstanding as of December 31, 2025

6,884,390

$

25.75

  ​ ​ ​

  ​ ​ ​

  ​ ​ ​

  ​ ​ ​

Options granted

1,828,360

19.15

Options exercised

(178,389)

12.42

Options forfeited

(46,506)

30.29

Options expired

(428,794)

22.35

Outstanding as of June 30, 2026

8,059,061

$

24.71

6.24

$

11,330

Exercisable as of June 30, 2026

4,952,155

24.51

4.44

$

9,452

Vested and expected to vest as of June 30, 2026

7,807,326

24.75

6.14

$

11,161

(1)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company’s stock for those awards that have an exercise price below the estimated fair value at June 30, 2026.

For the three and six months ended June 30, 2026, the Company recorded expense of $3.3 million and $8.0 million, respectively, related to stock options granted under all plans. For the three and six months ended June 30, 2025, the Company recorded expense of $3.0 million and $7.2 million, respectively, related to stock options granted under all plans.

Information relating to option grants and exercises is as follows:

Three Months Ended

Six Months Ended

 

June 30, 

June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

 

(in thousands, except per share data)

 

Weighted-average grant date fair value per share

$

8.78

$

11.81

$

9.27

$

13.25

Intrinsic value of options exercised

 

67

2,922

1,791

10,755

Cash received from options exercised

 

312

3,318

2,162

5,386

Total fair value of the options vested during the period

 

1,133

1,136

13,043

11,814

A summary of the status of the Company’s non-vested options as of June 30, 2026, and changes during the six months ended June 30, 2026, are presented below:

  ​ ​ ​

  ​ ​ ​

Weighted-Average

Grant Date

Options

Fair Value

Non-vested as of December 31, 2025

2,153,209

$

15.73

Options granted

 

1,828,360

9.27

Options vested

 

(828,157)

15.75

Options forfeited

 

(46,506)

14.35

Non-vested as of June 30, 2026

 

3,106,906

 

11.95

As of June 30, 2026, there was $29.3 million of total unrecognized compensation cost, net of forfeitures, related to non-vested stock options granted under all plans. The cost is expected to be recognized over a weighted-average period of 2.8 years and will be adjusted for future changes in estimated forfeitures.

Restricted Stock Units

The Company grants restricted stock units, or RSUs, to certain employees and members of the Board of Directors with a vesting period of up to four years. The grantee receives one share of common stock at a specified future date for each RSU awarded. The RSUs may not be sold or otherwise transferred until vested. The RSUs do not have any voting or dividend rights prior to the issuance of the underlying common stock. The share-based compensation expense associated with these grants was based on the Company’s common stock fair value at the time of grant and is amortized over the requisite service period, which generally is the vesting period, using the straight-line method. For the three and six months ended June 30, 2026, the Company recorded total expenses of $3.4 million and $7.7 million, respectively, related to RSU awards granted under all plans. For the three and six months ended June 30, 2025, the Company recorded expenses of $3.1 million and $7.0 million, respectively, related to RSU awards granted under all plans.

As of June 30, 2026, there was $30.4 million of total unrecognized compensation cost, net of forfeitures, related to non-vested RSUs granted under all plans. The cost is expected to be recognized over a weighted-average period of 2.8 years and will be adjusted for future changes in estimated forfeitures.

Information relating to RSU grants and deliveries is as follows:

Total Fair Market

Total RSUs

Value of RSUs

  ​ ​ ​

Issued

  ​ ​ ​

Issued(1)

(in thousands)

RSUs outstanding at December 31, 2025

 

1,007,433

RSUs granted

 

884,859

$

16,942

RSUs forfeited

 

(22,059)

RSUs vested(2)

 

(382,871)

RSUs outstanding at June 30, 2026

 

1,487,362

(1)The total FMV is derived from the number of RSUs granted times the current stock price on the date of grant.
(2)Of the vested RSUs, 135,340 shares of common stock were surrendered to fulfill tax withholding obligations.

Share-based Compensation Expense

The Company recorded share-based compensation expense, which is included in the Company’s condensed consolidated statements of operations, as follows:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

2026

2025

2026

 

2025

(in thousands)

Cost of revenues

  ​ ​ ​

$

1,557

  ​ ​ ​

$

1,400

  ​ ​ ​

$

4,013

  ​ ​ ​

$

3,738

Operating expenses:

Selling, distribution, and marketing

 

359

311

719

624

General and administrative

 

4,513

4,068

9,650

8,637

Research and development

 

661

603

1,982

1,776

Total share-based compensation expense

$

7,090

$

6,382

$

16,364

$

14,775